Literature DB >> 19258270

Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.

Rina P M Wong1, Timothy M E Davis.   

Abstract

The in vitro sensitivity of Plasmodium falciparum to atorvastatin and rosuvastatin was assessed using chloroquine-sensitive and chloroquine-resistant strains. Although atorvastatin was more potent, it had weak activity (mean 50% inhibitory concentration of > or = 17 microM) and an indifferent interaction with chloroquine and dihydroartemisinin. Bioassay of plasma from an atorvastatin-treated subject showed similar results.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19258270      PMCID： PMC2681572          DOI： 10.1128/AAC.01469-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase.

Authors:  A Montalvetti; J Peña-Díaz; R Hurtado; L M Ruiz-Pérez; D González-Pacanowska
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Plasmodium falciparum: the lethal effects of tunicamycin and mevastatin on the parasite are not mediated by the inhibition of N-linked oligosaccharide biosynthesis.

Authors:  R S Naik; M Venkatesan; D C Gowda
Journal:  Exp Parasitol       Date:  2001-06       Impact factor: 2.011

3.  Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans.

Authors:  Jia L Song; Chris N Lyons; Scott Holleman; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2003-10       Impact factor: 4.076

4.  Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria.

Authors:  Robin Kobbe; Nadine Schreiber; Jürgen May; Thomas Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

Review 5.  Effectiveness of statin therapy in adults with coronary heart disease.

Authors:  Timothy J Wilt; Hanna E Bloomfield; Roderick MacDonald; David Nelson; Indulis Rutks; Michael Ho; Gregory Larsen; Anthony McCall; Sandra Pineros; Anne Sales
Journal:  Arch Intern Med       Date:  2004-07-12

6.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Authors:  Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

Review 7.  Rosuvastatin: efficacy, safety and clinical effectiveness.

Authors:  Handrean Soran; Paul Durrington
Journal:  Expert Opin Pharmacother       Date:  2008-08       Impact factor: 3.889

8.  Comparison of bioassay and high performance liquid chromatographic assay of artesunate and dihydroartemisinin in plasma.

Authors:  B M Kotecka; K H Rieckmann; T M E Davis; K T Batty; K F Ilett
Journal:  Acta Trop       Date:  2003-08       Impact factor: 3.112

9.  Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro.

Authors:  Geoff A Butcher; Robert E Sinden
Journal:  Am J Trop Med Hyg       Date:  2003-01       Impact factor: 2.345

10.  Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation.

Authors:  Drew M Catron; Yvonne Lange; Jayme Borensztajn; Matthew D Sylvester; Bradley D Jones; Kasturi Haldar
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441
View more
  6 in total

1.  Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.

Authors:  Hélène Savini; Jean Baptiste Souraud; Sébastien Briolant; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

2.  In vitro antimalarial activity and drug interactions of fenofibric acid.

Authors:  Rina P M Wong; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

3.  Antileishmanial effect of mevastatin is due to interference with sterol metabolism.

Authors:  Neeradi Dinesh; Neelagiri Soumya; Sushma Singh
Journal:  Parasitol Res       Date:  2015-07-18       Impact factor: 2.289

4.  Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.

Authors:  Carmen María Martín-Navarro; Jacob Lorenzo-Morales; Rubén P Machin; Atteneri López-Arencibia; José Manuel García-Castellano; Isabel de Fuentes; Brendan Loftus; Sutherland K Maciver; Basilio Valladares; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

Review 5.  Are there any benefits from statin treatment for the septic patient?

Authors:  Peter S Kruger; Bala Venkatesh
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

6.  A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations.

Authors:  Hassan A Alhazmi; Ahmed M Alnami; Mohammed A A Arishi; Raad K Alameer; Mohammed Al Bratty; Zia Ur Rehman; Sadique A Javed; Ismail A Arbab
Journal:  Sci Pharm       Date:  2017-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.